BrainsWay Ltd. American Depositary Shares (BWAY)

About BWAY

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzhei…

Sector

Health Care

Industry

Medical/Dental Instruments

Employees

129

Website

www.brainsway.com/

Fundamentals

1-day range

$14.09$14.67

Market cap

$632.92M

P/E (trailing)

72.19

P/E (forward)

29.38

EPS (trailing)

$0.23

Dividend yield

—

Beta

0.83

Avg. volume

121.6K

Forecasts

3 analyst ratings

BrainsWay Ltd. American Depositary Shares Competitors

Chosen by industry and closest market cap.

• BWAY

  BrainsWay Ltd. American Depositary Shares

  $14.29

  ▼ 0.76%
  Market cap $632.92MP/E 72.19
  $2,391$5,123
• TCMD

  Tactile Systems Technology Inc. Common Stock

  $23.15

  ▲ 0.17%
  Market cap $671.73MP/E 26.91
  $12.91$37.77
• KIDS

  OrthoPediatrics Corp. Common Stock

  $23.67

  ▲ 1.50%
  Market cap $536.05MP/E —
  $14.42$26.74
• SSII

  SS Innovations International Inc. Common Stock

  $3.5

  ▲ 2.34%
  Market cap $790.52MP/E —
  $3.11$10
• NPCE

  Neuropace Inc. Common Stock

  $14.41

  ▲ 1.98%
  Market cap $460.27MP/E —
  $8.76$19.6
• MOBI

  Mobia Medical Inc. Common Stock

  $11.37

  ▲ 7.22%
  Market cap $377.38MP/E —
  $10.19$15.29
• TMCI

  Treace Medical Concepts Inc. Common Stock

  $4.67

  ▲ 1.41%
  Market cap $303.61MP/E —
  $1.17$7.63

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• BrainsWay Says Secondary Analysis Of Deep TMS Trial Published In Journal Of Affective Disorders Showed Suicidal Ideation Fell From 22.5% Of 89 Patients At Baseline To 6.7% At Six Weeks
  benzinga · 8/27/2026
• BrainsWay: Market Saturation And Competition Could Be Issues
  SeekingAlpha · 8/13/2026
• Ladenburg Thalmann Maintains Buy on BrainsWay, Raises Price Target to $18.8
  Benzinga · 8/13/2026
• BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/12/2026
• BTIG Maintains Buy on BrainsWay, Raises Price Target to $20
  Benzinga · 8/12/2026
• BrainsWay Raises FY2026 Sales Guidance from $66.000M-$68.000M to $68.000M-$70.000M vs $67.819M Est
  Benzinga · 8/12/2026
• BrainsWay Q2 EPS $0.07 Misses $0.08 Estimate, Sales $17.107M Beat $16.497M Estimate
  Benzinga · 8/12/2026
• BrainsWay: Building A Capital-Light Interventional Psychiatry Ecosystem
  SeekingAlpha · 8/6/2026

• Gilad Moiseyev · June 15, 2026 · Sale

  5.0K
• Yiftach Roth · June 2, 2026 · Sale

  2.0K
• Yiftach Roth · June 2, 2026 · Sale

  1.0K
• Yiftach Roth · June 1, 2026 · Sale

  2.0K
• Rayten Michal Ety Mitrany · May 26, 2026 · Sale

  8.0K
• Gilad Moiseyev · May 25, 2026 · Option Exercise

  7.5K
• Gilad Moiseyev · May 25, 2026 · Tax Withholding

  1.9K
• Rayten Michal Ety Mitrany · May 25, 2026 · Sale

  10.0K
• Rayten Michal Ety Mitrany · May 20, 2026 · Option Exercise

  17.5K
• Rayten Michal Ety Mitrany · May 20, 2026 · Tax Withholding

  6.1K
• Rayten Michal Ety Mitrany · May 19, 2026 · Option Exercise

  10.0K
• Rayten Michal Ety Mitrany · May 19, 2026 · Tax Withholding

  3.4K

Institutional Ownership

March 31, 2026

Total shares held

11.47M

Total value held

$140.51M

Institutional holders

53